Lung cancer is the leading cause of cancer-related deaths worldwide. Tumor suppressor genes remain to be systemically identified for lung cancer. Through the genome-wide screening of tumor-suppressive transcription factors, we demonstrate here that GATA4 functions as an essential tumor suppressor in lung cancer in vitro and in vivo. Ectopic GATA4 expression results in lung cancer cell senescence. Mechanistically, GATA4 upregulates multiple miRNAs targeting TGFB2 mRNA and causes ensuing WNT7B downregulation and eventually triggers cell senescence. Decreased GATA4 level in clinical specimens negatively correlates with WNT7B or TGF-β2 level and is significantly associated with poor prognosis. TGFBR1 inhibitors show synergy with existing therapeutics in treating GATA4-deficient lung cancers in genetically engineered mouse model as well as patient-derived xenograft (PDX) mouse models. Collectively, our work demonstrates that GATA4 functions as a tumor suppressor in lung cancer and targeting the TGF-β signaling provides a potential way for the treatment of GATA4-deficient lung cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458308 | PMC |
http://dx.doi.org/10.1038/s41467-019-09295-7 | DOI Listing |
Vaccine X
January 2025
Shinagawa Pharmaceutical Association, 2-4-2 Nakanobu, Shinagawa-ku, Tokyo 142-0053, Japan.
Objective: Owing to persistent concerns about side effects, human papillomavirus (HPV) vaccination rates in Japan have remained low. Pharmacists are therefore encouraged to improve vaccination rates by providing accurate information. This study evaluated the impact of educational interventions on pharmacists' knowledge and willingness to recommend the HPV vaccine.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Oncology, Bishan Hospital of Chongqing Medical University, Chongqing, China.
Background: Several head-to-head meta-analyses have compared the efficacy and safety of different first-line treatments in patients with EGFR mutation-positive (M+) advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC). However, there is a lack of comprehensive evaluation encompassing multiple treatment strategies. Our objective is to conduct a network meta-analysis that includes various treatment modalities, enabling both direct and indirect comparisons for a more thorough assessment.
View Article and Find Full Text PDFBackground: Rearranged during transfection () fusions represent a distinct molecular subset of non-small cell lung cancer (NSCLC) with targeted therapeutic potential. Selpercatinib, a highly selective inhibitor, has demonstrated efficacy in various solid tumors harboring alterations. Here, we present a case highlighting the use and clinical outcomes of selpercatinib in a patient diagnosed with advanced lung adenocarcinoma harboring a fusion.
View Article and Find Full Text PDFClin Med Insights Case Rep
January 2025
Infectious Disease Unit, Augusta Victoria Hospital, East Jerusalem, Palestine.
Introduction: is a common helminthic infection characterized by fecal-oral route of transmission. Commonly, it affects the gastrointestinal tract. However, in significantly rare cases, it can affect unexpected body regions, such as biliary tree, pancreas, and the lung.
View Article and Find Full Text PDFTob Induc Dis
January 2025
Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, United States.
Introduction: Cigarette smoking is an important risk factor in the development of dyspnea. Programs designed to strengthen the respiratory muscles can improve dyspnea in people with or without lung disease. As a first step in understanding the feasibility of offering a respiratory muscle training (RMT) program to people who are seeking help to try to quit smoking, we asked callers who contacted the New York State Quitline about their dyspnea and potential interest in a home-based RMT program.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!